EcoDrugPlus

Ensembl ID : ENSPNAG00000023005
Gene Symbol: -
Cross references: -
124 Possible Orthologues:

Ensembl ID : ENSPNAG00000012639
Gene Symbol: -
Cross references: -
196 Possible Orthologues:

Ensembl ID : ENSPNAG00000014115
Gene Symbol: RPLP0
1 Cross references
397 Possible Orthologues:

Ensembl ID : ENSPNAG00000009272
Gene Symbol: -
Cross references: -
199 Possible Orthologues:

Ensembl ID : ENSPNAG00000009465
Gene Symbol: -
Cross references: -
157 Possible Orthologues:

Ensembl ID : ENSPNAG00000015635
Gene Symbol: -
Cross references: -
182 Possible Orthologues:

Ensembl ID : ENSPNAG00000018097
Gene Symbol: -
Cross references: -
192 Possible Orthologues:

Ensembl ID : ENSPNAG00000018479
Gene Symbol: -
Cross references: -
192 Possible Orthologues:

Ensembl ID : ENSPNAG00000024090
Gene Symbol: -
Cross references: -
182 Possible Orthologues:

Ensembl ID : ENSPNAG00000025634
Gene Symbol: -
Cross references: -
186 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).